CDK5 PLAYS A KEY ROLE IN PROLIFERATION, APOPTOSIS, AND IN VIVO TUMOR GROWTH OF DIFFUSE LARGE B-CELL LYMPHOMA by A. Inguscio
	  UNIVERSITÀ DEGLI STUDI DI MILANO 
 
Facoltà di Medicina e Chirurgia 
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale 
 
 
 
 DOTTORATO DI RICERCA IN 
BIOTECNOLOGIE APPLICATE ALLE SCIENZE MEDICHE - CICLO XXVII 
Scuola di Dottorato in Scienze Biomediche Cliniche e Sperimentali 
 
 
TESI DI DOTTORATO DI RICERCA 
 
CDK5 PLAYS A KEY ROLE IN PROLIFERATION, 
APOPTOSIS AND IN VIVO TUMOR GROWTH OF 
DIFFUSE LARGE B-CELL LYMPHOMA  
 
Settore BIO/13 – Biologia Applicata 
 
 
DOTTORANDO 
Alessandra Inguscio 
 Matr. R09800 
RELATORE   
Prof. Carmelo Carlo-Stella 
 
CORRELATORE  
Dott.ssa Manuela Quintavalle 
 
Anno Accademico 2013/2014
 
 
 
 
 
 
 
 
 
 
 
To Gabriele, my mother and my father. 
 
To Ivaldo, who has believed in me. 
 
	  	  
	  	   2	  
 
TABLE OF CONTENTS 
 
 
ABSTRACT ............................................................................................................. 4 
1. INTRODUCTION .................................................................................................. 6 
1.1 – DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) ............................... 7 
1.2 – CYCLIN-DEPENDENT KINASE 5 (CDK5) ........................................... 14 
1.2.1 – Cdk5, an unusual member of Cdk family ......................................... 14 
1.2.2 – Regulation of transcription and translation by Cdk5 ...................... 15 
1.2.3 Cdk5 and the control of the cell cycle ................................................... 17 
1.2.4 – Role of Cdk5 in apoptosis .................................................................... 20 
1.2.5 – Role of Cdk5 in the immune system function and inflammation .. 21 
1.2.6 – Cdk5 and cancer .................................................................................... 23 
1.3 – MicroRNA .................................................................................................... 27 
1.3.1 – miRNA and cancer ................................................................................ 32 
1.3.2 – Role of miRNAs in the hallmarks of human cancer ........................ 33 
1.3.3 – miR26a and cancer ................................................................................ 36 
1.3.4 – Rational for targeting miRNA ............................................................. 37 
1.3.5 – miRNA-based therapeutic strategies ................................................. 38 
2. AIM ......................................................................................................................... 40 
3. MATERIAL AND                 METHODS .......................................................... 42 
3.1 – REAGENTS .................................................................................................. 43 
3.2 – CELL LINES ................................................................................................. 43 
3.3 – GENERATION OF LOSS- AND GAIN-OF-FUNCTION CDK5/P35 
OR MIR-26A STABLE DLBCL CELL LINES ................................................. 44 
3.4 – VIRAL INFECTION OF DLBCL CELL LINES ..................................... 44 
3.5 – APOPTOSIS ASSAYS ................................................................................ 45 
3.6 – CELL CYCLE ANALYSIS .......................................................................... 45 
3.7 – WESTERN BLOT ANALYSIS .................................................................. 45 
3.8 – RNA EXTRACTION AND REAL-TIME PCR ....................................... 46 
3.9 – LUCIFERASE ASSAY ................................................................................ 46 
	  	  
	  	   3	  
3.10 – IN VIVO TUMOR GROWTH OF ENGINEERED             SU-DHL-8 
CELL LINES IN NON-OBESE DIABETIC/SEVERE COMBINED 
IMMUNODEFICIENT (NOD/SCID) MICE. .................................................. 47 
3.11 – HISTOLOGICAL ANALYSIS AND 
IMMUNOHISTOCHEMISTRY ........................................................................ 48 
3.12 – BIOINFORMATICS ................................................................................. 48 
3.13 – STATISTICAL ANALYSIS ..................................................................... 48 
4. RESULTS ............................................................................................................... 50 
4.1 – CDK5 AND ITS ACTIVATOR P35 ARE OVEREXPRESSED IN 
LYMPHOMA CELL LINES AND REGULATE THE 
PHOSPHORYLATION AND ACTIVITY OF STAT3 .................................. 51 
4.2 – CDK5 ACTIVITY IN DLBCL CELL LINES IMPAIRS 
PROLIFERATION ............................................................................................... 53 
4.3 – CDK5 ACTIVITY IS REQUIRED TO PROTECT DLBCL CELLS 
FROM APOPTOSIS ............................................................................................ 56 
4.4 – MIR-26A REPRESSES P35 EXPRESSION ............................................. 61 
4.5 – MIR-26A MODULATES PROLIFERATION AND CELL CYCLE 
PROGRESSION OF DLBCL CELLS THROUGH P35 REGULATION .... 63 
4.6 – MIR-26A MODULATES IN VIVO TUMOR GROWTH OF DLBCL 
THROUGH P35 REGULATION ....................................................................... 67 
5. DISCUSSION AND CONCLUSIONS ............................................................ 70 
BIBLIOGRAPHY .................................................................................................. 75 
 
 
 
 
 
  
	  	  
	  	   4	  
ABSTRACT 
 
Diffuse Large B-cell lymphoma (DLBCL) is the most common adult non-
Hodgkin lymphoma, whose standard of care is the immunochemotherapy R-
CHOP. Chemorefractory patients, still approximately 40%, represent an 
unmet medical need, requiring novel targets for innovative treatments. One 
potential target is cyclin-dependent kinase 5 (CDK5), a serine/threonine 
protein kinase that has been recently linked to tumor development and 
progression. 
Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine protein kinase, which 
forms active complexes with p35 or p39 and it is mostly active in the nervous 
system, regulating several processes. In the past few years, novel roles for 
Cdk5 have been proposed in many pathological conditions and cancer, even if 
its role in DLBCL remains uninvestigated to date. 
For the first time, we showed that Cdk5 and p35 are both overexpressed in 
DLBCL cell lines. Moreover, we highlighted that proliferation and apoptosis 
are regulated by Cdk5 activity in loss-of-function experiments. 
MicroRNAs (miRNAs) are a class of highly conserved short RNAs that 
regulate diverse cellular processes by degradation or translation inhibition of 
mRNA targets. Numerous reports have shown that miRNA dysfunction is 
involved in the development and progression of various human cancers (4).  
In particular, miR26a has a tumor suppressor role in different cancers, such as 
nasopharyngeal carcinoma (5) breast cancer (6) and gastric carcinoma (7), but 
its role in DLBCL remains still unclear. 
 
	  	  
	  	   5	  
In this study we demonstrated that mir-R26 regulates p35 expression and that 
it involves Cdk5/p35 pathway directly affecting DLBCL cells proliferation 
and apoptosis. Thus, the clarification of the molecular mechanisms at the base 
of Cdk5/p35 expression and their role on DLBCL tumor cell proliferation 
could lead to the identification of innovative therapeutic targets for 
treatments of DLBCL. 
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1. INTRODUCTION 
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1.1 – DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) 
Diffuse Large B-cell lymphoma (DLBCL) is the most common adult B-cell 
non-Hodgkin lymphoma (NHL), comprising 30–35% of all NHLs and 
accounting up to 30% newly diagnosed cases in the United States1. DLBCL 
represents a widely heterogeneous group of tumors from a point of view of 
clinical features, genetic abnormalities, response to treatment and prognosis2. 
It could arise inside the lymph nodes, but also outside of the lymphatic 
system, in several different locations in the body, such as skin, breast, 
gastrointestinal tract, testes, thyroid, brain, or bone.  
The first sign of the disease is a rapid and painless enlarging lymph nodes, 
that cause swelling in the neck, groin, or armpit. Sometimes the swelling 
could be painful. Other symptoms include unexplained fevers, weight loss, 
and night sweats. 
The diagnosis is made on the basis of a surgical biopsy/excisional lymph 
node or extranodal tissue specimen that are fixed in formalin. In those rare 
cases requiring emergency treatment, core biopsies could be appropriate as 
the only diagnostic test. The specimens are analyzed by 
immunohistochemistry (CD20, CD45, and CD3) and also the fresh frozen 
material is collected for molecular characterization by gene expression 
profiling (GEP). To ensure adequate quality, tissue specimens are processed 
and examined by an experienced pathologist. The diagnosis is given from the 
histological report according to the classification of the World Health 
Organization (WHO)3. The WHO classification aims to define “real” diseases 
on the bases of morphology, genetic characteristics, immunophenotype, and 
clinical features4. 
Through molecular characterization using gene‐expression profiling (GEP), 
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DLBCL can be subdivided into three distinct cell‐of‐origin subtypes: activated 
B‐cell (ABC), germinal centre B‐cell (GCB), and primary mediastinal B‐cell 
lymphoma (PMBL)5-8 (Figure 1.1). The molecular pattern of each subtypes 
correspond to the genes overexpressed in the putative B cell developmental 
stage from which the tumor originated: in the GCB subtype genes associated 
with the germinal center reaction are overexpressed, such as LMO2 and 
LRMP7; while the ABC subtype is characterized the overexpression of IRF4, 
FOXP1 and PIM27, that are genes that regulate the plasmacytic differentiation, 
deriving this subtypes from a post-germinal center B cell, and by the 
constitutive activation of NF-KB pathway; finally, the PMBL subtype derived 
from the rare post-thymic B cell and its molecular pattern is more similar to 
which that characterized classic Hodgkin lymphoma, than those of the other 
DLBCL subtypes6,9. 
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Fig. 1.1 – Morphologically indistinguishable DLBCL tumours can be subdivide by gene-
expression profiling into three distinct cell-of-origin subtypes. From Roschewski M. et al., 
Diffuse Large B-cell lymphoma – treatment approaches in the molecular era. Nat. Rev. Clin. 
Oncol. (2014) 
 
GEP allowed the identification of new potential targets and oncogenic 
mechanisms (Table 1.1), providing novel therapeutic options and the 
biological basis for targeted treatment of DLBCL, including the use of 
different classes of biological agents, and monoclonal antibodies.10 Targeting 
specific oncogene that is overexpressed in a specific subtypes allows a more 
accurate approach to therapy11 compared with the standard approaches based 
on chemotherapy. However, to develop personalized treatment for single 
patient, the identification of mutations driving disease progression and 
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tumorigenesis is not sufficient for the DLBCL molecular complexity.12 
Characterization of cooperating mutations that lead to drug resistance have to 
be keep into account. 
Table 1.1 | Oncogenic mechanisms and potential targets in DLBCL subtypes. From 
Roschewski M. et al., Diffuse Large B-cell lymphoma – treatment approaches in the molecular 
era. Nat. Rev. Clin. Oncol. (2014) 
  
DLBCL subtype  Cell of origin  Oncogenic mechanisms  Potential targets  
GCB  Germinal centre B-cell  
BCL2 translocation* EZH2 
mutations‡ !PTEN deletions§ !Loss 
of PTEN expression  
BCL6 EZH2 PI3K/Akt  
ABC  Post-germinal centre B-cell  
NF-κB activation|| CARD11 
mutations MYD88 mutations 
CD79B mutations A20 deletions  
BCR !CBM complex 
IRAK-4 JAK–STAT  
PMBL  Post-thymic B-cell  
NF-κB activation¶ 9p24 
amplification¶ REL 
amplification JAK2 mutations 
CIITA translocations#  
JAK–STAT PD-1#  
*GCB DLBCL frequently has BCL2 translocations13 and most result in activation of BCL-6, the master transcriptional 
regulator of the germinal centre.14 ‡Mutations in EZH2 (21% of GCB DLBCL cases) are specific for this subtype.15 
§Loss of PTEN expression (55% of GCB DLBCL cases)16 results in activation of the PI3K/Akt pathway for which 
multiple inhibitors are currently in development. ||ABC DLBCL is defined by constitutive NF-κB pathway 
activation17 and BCR signalling pathways are oncogenically activated in this subtype:18 mutations in MYD88, 
CARD11 and CD79B are found in ABC DLBCL along with deletions and mutations of TNFAIP3.19,20 ¶PMBL is 
characterized by amplification of chromosome 9p24 and NF-κB pathway activation.21#PDL1 and PDL2 are 
overexpressed in PMBL6 making their receptor, PD-1, a potential target; recurrent CIITA translocations also result in 
PD-1 pathway activation in PMBL.22 Abbreviations: ABC, activated B-cell; BCR, B-cell receptor; CBM, CARD11–
MALT1–BCL-10; DLBCL, diffuse large B-cell lymphoma; GCB, germinal centre B-cell; MALT1, mucosa-associated 
lymphoid tissue lymphoma translocation protein 1; PMBL, primary mediastinal B-cell lymphoma.  
 
Staging and risk assessment of DLBCL are based on a complete blood count, a 
screening test for hepatitis B and C and human immunodeficiency virus as 
well as routine blood chemistry including uric acid and lactate 
dehydrogenase (LDH), and protein electrophoresis. Patients sensible to 
curative therapy have a computed tomography (CT) scan of the abdomen and 
chest, bone marrow aspirate and biopsy; whereas high-risk patients do a 
diagnostic spinal tap in addition. The extension of the disease and the 
evaluation of treatment response in patient, are assessed by 
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[18F]deoxyglucose positron emission tomography (PET) scanning23. Finally, 
before therapeutic treatment, also the cardiac function (left ventricular 
ejection fraction) and the performance status of the patient are evalueted. 
The staging of DLBCL is established in accordance with the Ann Arbor 
staging system (Table 1.2)3. This system defines the extent of disease 
progression and helps predict prognosis and direct treatment. Four stages are 
described followed by the letter A or B, indicating the absence (A) or presence 
(B) of B symptoms. 
 
Table 1.2 
Ann Arbor staging classification. From Tilly, H. et al. Diffuse large B-cell 
lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Annals of oncology (2012) 
STAGE SYMPTOMS 
1 Involvement of a single lymphatic region or localized involvement 
of single extralymphatic organ or site  
2 
Involvement of two or more lymphatic regions on the same side of 
the diaphragm or localized involvement of a single extralymphatic 
organ or site and of one or more lymphatic regions on the same 
side of the diaphragm 
3 Involvement of lymphatic regions on both sides of the diaphragm  
4 Diffuse or disseminated involvement of one or more 
extralymphatic organs with or without lymphatic involvement  
 
 
The standard treatment for patients with DLBCL is an immunochemotherapy 
regimen in which Rituximab, a monoclonal antibody against CD20, is in 
combination with cyclophosphamide, doxorubicin, vincristine, and 
prednisone (R-CHOP).24 This therapy can cure more than 50% of cases, even 
in advanced stage, despite DLBCL is biologically aggressive.25 However, 
disease in up to one-third of patients will relapse or is refractory to therapy.26 
The salvage treatment for patients that have relapsed or refractory DLBCL 
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that are responsive to a second chemotherapy regimen, is autologous stem 
cell transplantation (ASCT), but the rates of success are poor nowadays27, 
requiring the identification of novel targets for innovative treatments.  
The International Prognostic Index (IPI) is the clinical prognostic tool 
commonly used to predict the overall treatment outcome in DLBCL patients, 
based on the age, serum lactate dehydrogenase (LDH) concentration, tumor 
stage, number of extranodal disease site and performance28, but this risk 
stratification tool does not capture the molecular heterogeneity and the 
genetic of the disease, leaving a large group of patients poorly-characterized 
and with an unfavorable course of disease, despite a good prognostic index.28 
The three distinct subtypes of DLBCL identified by GEP have different 
mechanisms of oncogenic activation as previously described, and also distinct 
prognosis (Table 1.3).10 
Table 1.3 | PFS and overall survival for each DLBCL molecular subtype.  From 
Roschewski M. et al., Diffuse Large B-cell lymphoma – treatment approaches in the molecular 
era. Nat. Rev. Clin. Oncol. (2014) 
Molecular 
subtype  Regimen  
3-year PFS 
rate  
3-year overall 
survival rate  Reference  
ABC DLBCL  R-CHOP  40%  Approximately 45%  Lenz et al. (2008)29  
GCB DLBCL  R-CHOP  74%  Approximately 80%  Lenz et al. (2008)29  
PMBL  DA-EPOCH-R  100%*  97%*  Dunleavy et al. (2013)16  
*At 5 years. Abbreviations: ABC, activated B-cell; DA-EPOCH-R, dose-adjusted etoposide, doxorubicin and 
cyclophosphamide with vincristine, prednisone and rituximab; DLBCL, diffuse large B-cell lymphoma; GCB, 
germinal centre B-cell; PFS, progression-free survival; PMBL, primary mediastinal B-cell lymphoma; R-CHOP, 
rituximab, cylophosphamide, doxorubicin, vincristine and prednisone.  
 
Patients with PMBL can be treated with another chemotherapeutic regimen, 
called DA-EPOCH-R.29 The Lymphoma/Leukemia Molecular Profiling 
Project (LLMPP) retrospective analysis showed that patients with ABC 
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DLBCL have worst prognoses than those with GCB DLBCL when treated 
with R-CHOP.30 Multiple reports have reveled that the over-expression of Bcl-
2 and Myc in DLBCL is associated with poor prognosis. These over-
expressions can be verified through immunohistochemistry on formalin-fixed 
paraffin embedded tissue.31-33 Nevertheless, it has not been proved if patients 
with both Bcl-2 and Myc expression are a molecularly different group.  
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1.2 – CYCLIN-DEPENDENT KINASE 5 (CDK5) 
Cdk5 belongs to Cyclin-dependent kinases (Cdks) family. The proteins of this 
family are kinases that specifically phosphorylate threonine or serine residues 
in different proteins that are involved in the regulation of the cell cycle. The 
Cdk family is composed of 9 small serine/threonine kinases (30–35 kDa), 
numbered from Cdk1 to Cdk9, according to their discovery.34 Cdks are 
involved in several biological functions, mitosis, regulation of cellular 
processes, such as senescence, differentiation and apoptosis, through gene 
transcription modification.35 In proliferating cells, dysregulation of Cdks lead 
to tumor formation, whereas their inhibition in neuronal precursors leads to 
terminal differentiation.36 Generally, to be activated, Cdks require the binding 
of an activator protein, named a cyclin, and the phosphorylation in a loop of 
activation.37,38 
Although specific Cdks are associated with different cell cycle phases, their 
activities can sometimes overlap, depending on the binding with different 
cyclins.34,39,40 
 
1.2.1 – Cdk5, an unusual member of Cdk family 
Despite Cdk5 shares a strong sequence homology with other members of 
Cdks family, it is an unusual member because it’s activation does not require 
either to be phosphorylated or the binding of a cyclin, but of another activator 
protein, termed p35.41 However, unlike other cyclin-dependent kinases whose 
principal function is to regulate the cell cycle progression, most Cdk5 target 
proteins are not implicated in the control of cell cycle, but are involved in 
neuronal signaling or cytoskeleton.42,43 Indeed, in literature there are many 
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evidences that Cdk5 controls different neuronal processes, such as cell 
adhesion, pain signaling, neuronal migration, actin dynamics, apoptosis, 
microtubules stabilization and transport, axonal guidance, synaptic structure 
and endocytosis.44-46 The consensus motif phosphorylated by Cdk5 in proteins 
is (S/T)PX(K/H/R). However also some sequence variations can be 
phosphorylated, such as the KSPXX motif in the neurofilaments47 and KSPXK 
in the microtubule-associated protein 1B.42 Cdk5 activation requires the 
binding to its non-cyclin activators p39 or p35.48,49 When it is bound to Cdk5, 
p35 adopts a structural conformation comparable to those of a cyclin.50 The 
abundance of p39 and p35 in the nervous system cause the prominent activity 
of Cdk551, which has a key role in function and development of the nervous 
system.52-54  
In the last ten years, numerous studies have demonstrated that Cdk5 is active 
also in many different non-neuronal cells55, such as pancreatic β cells56, 
monocytes57, corneal epithelial cells58, ovary59, testis55. Recently, its 
involvement in many other different biological mechanisms, such as 
activation of immune system, cell migration, angiogenesis, gene expression, 
apoptosis and proliferation, in many different cell types is raised. 
1.2.2 – Regulation of transcription and translation by Cdk5  
 
Cdk1, Cdk2, Cdk6, and Cdk4 have a key role in the cell cycle regulation, 
providing a check-point system in its progression38. Nevertheless, some other 
members of the family, such as Cdk9, Cdk8, and Cdk7, regulate the cell cycle 
in an indirect manner by the modulation of the function of many different 
transcription factors.60,61 All of these Cdks activated by cyclins can 
phosphorylate the RNA polymerase II C-terminal domain, thus they 
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modulate expression of specific genes and have a role in chromatin regulation 
and RNA processing.62,63 It is reasonable that also Cdk5 might be involved in 
gene expression regulation, because Cdk5/p35 complex is found in the 
nucleus64, and because some Cdk5 target proteins are transcription factors, 
such as myocyte enhancer factor 265 and p5366. In particular, a study has 
reported that in the nucleus the active Cdk5/p35 complex can phosphorylate 
mSin3-associated protein (mSds3), a fundamental component of the mSin3–
histone deacetylase complex67, to regulate the function of RNA polymerase 
II68, repressing transcription. Interestingly, Cdk5 can also phosphorylate the 
ubiquitous and the most abundant cromatin-associated non-histone protein, 
the high mobility group box 1 (HMGB1) at Ser180, inducing its binding to 
DNA69 and structural changes that cause the transcription factors 
recruitment70. Finally, in the cytoplasm Cdk5 can phosphorylate a 
transcription factor activated in hypertonic conditions, the tonicity-responsive 
enhancer binding protein (TonEBP)71. In this condition,  TonEBP is 
phosphorylated and transported to the nucleus, where osmoprotective genes 
are transcripted72 (Figure 1.2). 
Recently, some studies have been demonstrated that Cdk5 controls also 
translation.73 Cdk5 can phosphorylate the glutamyl-prolyl tRNA synthetase 
(EPRS) at Ser886, after interferon-gamma (IFN-γ) stimulation, which in turn 
can down-regulate the mRNA translation of encoding pro-inflammatory 
molecules, binding the GAIT complex in myeloid cells74,75. Of note, this is the 
first study linking Cdk5 role with the regulation of translation (Figure 1.2). 
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Fig. 1.2 – The role of Cdk5 in controlling transcription (blue background panels) and 
translation (gray background panel). A) The active Cdk5/p35 complex may be localized in 
the nucleus where it phosphorylates mSds3 to regulate the function of RNA polymerase II. B) 
In another cellular context, Cdk5 can phosphorylate HMBG1 to promote transcription. C) 
Finally, Cdk5 can phosphorylate TonEBP in the cytoplasm. Phosphorylated TonEBP is 
transported to the nucleus where it can stimulate the transcription of osmoprotective genes. 
D) Finally, in response to interferon-gamma IFN-g Cdk5 can phosphorylate EPRS which then 
can bind the GAIT complex to down-regulate the translation of mRNA encoding pro-
inflammatory molecules. From Contreras-Vallejos ! E., et al. Going out of the brain: Non-
nervous system physiological and pathological functions of Cdk5. Cellular Signalling (2012) 
 
1.2.3 Cdk5 and the control of the cell cycle  
 
Cdk5 historically is an un common member of the Cdk family, in fact its 
activation requires a non-cyclin activators and does not need to be 
phosphorylated at the activation loop, as previously described. More 
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important, Cdk5 has been supposed to not play any function in the cell cycle 
control42,43. Recently, this view has been modified because it was found that 
Cdk5 might bind to cyclin I, that in turn may activate the kinase.76 In 
addiction, it has been observed that Cdk5 also might interact with other 
cyclins such as cyclin E, D3 and D1. Nevertheless, the interaction with these 
cyclins does not affect its kinase activity.77,78 
Remarkably, cyclin D2 also binds the Cdk5, but in this case, the activity of the 
Cdk5/p35 complex can be abrogated. A possible molecular explanation can 
be linked to the differential recognition of the Cip/Kip family members to 
Cdk5 when it forms a complex with cyclin D2 or p35.79  
Since the discovery of cyclin I, the classical opinion that the cyclins expression 
is regulated strictly during the different phases of the cell cycle has been 
modifying. In fact, cyclin I is not implicated in cell proliferation and continues 
to be equally expressed during the entire cell cycle.80,81 Of note, it is expressed 
mainly in terminally differentiated cells (cardiomyocytes, podocytes and 
neurons) and when cyclin I is absent these cells are more susceptible to 
apoptosis.81,82 The Cdk5/cyclin I complex was hypothesized to activate the 
MEK-ERK signaling pathway, leading to an augment of Bcl-2 and Bcl-XL 
expression in postmitotic cells; these variations in anti-apoptotic proteins are 
due to the activity of ERK1/2.83  
The Cdk5/p35 complex might also phosphorylate Bcl-2 at Ser70, inducing 
stabilization of this protein84, which indicates that Cdk5 can indeed be able to 
control apoptosis by two different and maybe independent mechanisms, 
suggesting that Cdk5 may have a fundamental role in controlling the survival 
of postmitotic cells. Moreover, Cdk5 also can interacted with cyclin G1, 
	  	  
	  	   19	  
causing to the phosphorylation of c-Myc at Ser62; this effect has been found 
primarily in lung carcinoma cells, in which both Cdk5 and cyclin G1 are up-
regulated.85 This study suggests that Cdk5 can have a key function in the 
regulation of the cell cycle in lung carcinoma cells which overexpress cyclin 
G1, and thus, it will be interesting to understand if Cdk5 has the same 
function in other cancers. 
In neurons, Cdk5/p35 complex leads to the cell cycle suppression interacting 
with the transcription factor E2F1 in the nucleus. This interaction impairs the 
assemblement of the E2F1/DP1 complex that modulates the activation of the 
transcription of different genes. A similar mechanism has not been still 
observed in other terminally differentiated cell types, such as cardiomyocytes 
and podocytes. During cell cycle arrest the CKI inhibitor, p21, represses E2F 
activity through the inhibition of the phosphorylation of Retinoblastoma 
protein (pRB)86. In this circumstance, Cdk5 can phosphorylate and thus 
stabilize p5366, which active the transcription of p21.87 Therefore, Cdk5 can 
control both pathways to block the progression of cell cycle in highly 
differentiated cells.  
Another remarkable aspect about the Cdk5 function in the cell cycle is 
correlated to the localization of p35, Cdk5 and Cdk5rap2, a protein involved 
in the stabilization of the centrosome and regulation of microtubule 
dynamics, at the centrosome of HeLa cells. The association between Cdk5rap2 
and centrosome is independent from microtubules.88 Mutated Cdk5rap2 leads 
to the primary microcephaly development. Interestingly, double knockout 
p35/p39 mice have a reduction in the body size compared with wild-type 
mice89, indicating the possibility that Cdk5 could regulate cell division. Of 
note, Cdk5rap2 is located in the midbody, an important structure in 
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cytokinesis. Defects in the midbody results in problems in cell division90. 
Similarly, Cdk5 also is located at the midbody in HeLa cells, but it has been 
demonstrated that its role in the control of cytokinesis can be independent of 
kinase activity.91  
 
1.2.4 – Role of Cdk5 in apoptosis  
 
Cdk5 involvement in apoptosis mechanisms has been mainly described in 
central nervous system, but recently also in other cells92 55.  
Sharma and colleagues have shown that Cdk5 is highly expressed in 
proliferating bovine aortic endothelial cells (EC).93 After inhibition of EC 
proliferation and stimulation of apoptosis by Angiotensin94 a significantly 
Cdk5 decrease was found. Furthermore, EC proliferation stimulation by basic 
fibroblast growth factor95, a pro-angiogenic growth factor, can be inhibited by 
roscovitine, an inhibitor of Cdk5, which instead can induce EC apoptosis.93 
Genetic and pharmacological inhibition of Cdk5 function is also linked with 
increased susceptibility to cell death in several different cell types96-98.  
p35 knockout mice present podocytes without aberrations and with normal 
morphology. Nevertheless, apoptosis is significantly increased in 
immortalized podocytes from p35 knockout mice exposed to different stress 
conditions, including depletion of serum, UV-C radiation, transforming 
growth factor β1 or puromycin aminonucleoside. Consistently with previous 
observations, apoptosis increases in podocytes from wild-type mice after 
transfection with siRNA against p35. Rescue experiments restoring p35 in 
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podocytes from p35 knockout mice decreases apoptosis.83 Effects of Cdk5 
activity on apoptosis in podocytes may be correlated to increased Bcl-2 
expression under the control of the Cdk5/p35 complex or, alternatively, a 
stabilizing effect of Cdk5 phosphorylation on Bcl-2.  
Cdk5 also has a key role in pancreatic β cells, in which extracellular glucose 
induce an increase in the p35 expression and subsequent Cdk5 activity, 
indicating that the secretion99 and transcription98 of insulin may be dependent 
on the Cdk5/p35 complex. Nevertheless, p35 overexpression can inhibit the 
secretion of insulin in pancreatic β cells. Therefore, Cdk5/p35 complex 
appears to be influenced by glucose levels. In high glucose conditions, p35 is 
overexpressed and a calpain-dependent p25 fragment of p35 is founded, 
resulting in apoptosis events and insulin secretion reduction. Both effects can 
be reversed by the use of the Cdk5 inhibitor. 
 
1.2.5 – Role of Cdk5 in the immune system function and 
inflammation 
 
 
Cdk5 seems to have a regulatory function also in the immune system, in 
which it may be involved in cellular activation and in control of the 
inflammatory response. Remarkably, Cdk5 can phosphorylate the 
intermediate filament protein vimentin at Ser56, leading to GTP-dependent 
secretion of proinflammatory molecules by neutrophils.  
Of note, when the Cdk5-dependent phosphorylation of vimentin increased, 
also the secretion of lactoferrin, matrix metalloprotease-9 and β-
hexosaminidase increased. Using Cdk5 siRNA or roscovitine this effect is 
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reduced considerably, but not abrogated, suggesting that other protein 
kinases can be implicated in the secretion of these molecules by neutrophils. 
Considering these evidence, Cdk5 is an attractive target to modulate 
neutrophil-mediated inflammatory responses by inhibiting the 
proinflammatory molecules secretion.100 
In another aspect of inflammation regulation, Cdk5 activation by p35 is 
requested for migration and proliferation of T cell receptor-dependent 
activation lymphocytes. Coronin 1a and F-actin are aberrantly polarized in 
lymphocytes derived from Cdk5 knockout mice, indicating that the Cdk5-
mediated phosphorylation of coronin1a is important for modulation of actin 
dynamics in T cells.  
Actin dynamics can have an essential role in T cell activation and CCL19-
dependent lymphocyte migration promotion, which are implicated in the 
pathophysiology of experimental autoimmune encephalomyelitis. Even if this 
autoimmune model involves the CNS, this Cdk5 novel function in the control 
of T cells opens new opportunities for innovative therapies for inflammatory 
diseases treatment.101  
Recently, it has been demonstrated that Cdk5 presents other functions in the 
inflammatory response. Berberich et al. demonstrated that pharmacological 
inhibition of Cdk5 causes the inhibition of the transmigration of leukocytes by 
blocking gene expression dependent by NFκB. These effects were reproduced 
by genetic inactivation of both Cdk5 and Cdk9 using siRNAs.102 
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1.2.6 – Cdk5 and cancer  
 
Similar molecular and cellular mechanisms mediate migration of cancer cells 
during metastasis and of neuronal cells during the nervous system 
development.103 Consequently, it is not surprising that Cdk5 can have a role 
also in the migration of tumor cells.  
Feldmann et al. demonstrated that the inhibition of Cdk5 activity, through the 
use of a pharmacological inhibitors or a dominant negative Cdk5, decreases 
the migration capacity of pancreatic carcinoma cells.104 Indeed, Cdk5 
inactivation leads morphological changes in these cells that induces to a loss 
of cell polarity.  
Of note, Cdk5 controls not only migration but also invasion through the 
modulation of the invadopodia formation.105 Consistent with these effects, 
Cdk5 inhibition decreases metastasis and tumor growth in pancreatic 
cancer.104 Therefore, Feldmann at al. focused on the Ras-dependent signaling 
pathway, which plays a key role in the development of pancreatic tumor106, 
showing a possible involvement of Cdk5, that Cdk5 could be an innovative 
target for the treatment of pancreatic tumor.104  
Another observation that link Cdk5 with the onset of tumors is that Cdk5 may 
phosphorylate and thus modulate the transcriptional activity of STAT3 at 
Ser727.57 In medullar thyroid carcinoma cells, STAT3 phosphorylated by Cdk5 
leads to an increase in cell proliferation and promotion of malignancy 
transformation. Moreover, aggregates of calcitonin derived from medullar 
thyroid carcinoma promote Cdk5 activity inducing cell proliferation. 
Consistently with these observations, inhibition of Cdk5 in nude mice retards 
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tumor growth in a STAT3 phosphorylation-dependent manner.107 
Cdk5 activity can be modulated also by retinoic acid in thyroid neoplastic 
cells through a plasma membrane glycoprotein that promotes the uptake of 
iodide.108 These observations suggest that Cdk5 may be a molecular target for 
the diagnosis and treatment of medullary thyroid cancer.  
In breast cancer, Cdk5 can have a key role in controlling proliferation of 
tumor cells, because in the presence of either siRNA against Cdk5 or 
roscovitine, MCF-7 and MDA- MB321 cells show a reduction in proliferation 
rates. Carboplatin treatment, a known chemotherapeutic drug against breast 
tumor, leads to Cdk5 activation through increased the ERK activity in 
response to DNA damage.107 Increased Cdk5 activity stabilizes p53 leading to 
cell death.107 Hence, strict regulation of Cdk5 activity can be fundamental for 
normal cell physiology because loss or gain of function can result in aberrant 
cell proliferation.  
In cervical carcinoma caused by infection of human papilloma virus (hPV), 
Cdk5 may phosphorylate p53 at Ser43 and Ser20, hence inhibiting cell 
proliferation. Nevertheless, hPV may cause p53 degradation. Indeed, HeLa 
cells infected by hPV do not undergo cell cycle arrest or apoptosis even when 
p53 is over-expressed. However, changing p53 phosphorylation state, either 
by inhibiting phosphatases or promoting the protein kinases activity, may 
induce apoptosis.109 In this case, Cdk5-dependent p53 phosphorylation should 
be an essential event that promotes increased stability of p53 and its 
transcriptional activation.66  
A previous report demonstrated that Cdk5 activity is fundamental to regulate 
cell motility and the metastatic potential of prostate tumor cells.110 Tumor cells 
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proliferation is increased by the improved stability of androgen receptor, after 
its phosphorylation by Cdk5/p35. Moreover, Hsu and colleagues found that 
Cdk5 may enhance both expression and secretion of prostate-specific antigen 
(PSA), which indicates that Cdk5 may play a key role in the development of 
prostate tumor.  
Cdk5 has been recently proposed to be a risk factor for other types of tumors, 
although the molecular mechanisms clarifying the relationship between 
cancer and Cdk5 is still elusive.111,112 Therefore, in some patients with non-
small cell lung cancer, there is a significant correlation between Cdk5/p35 
expression levels and the differentiation and metastasis to lymph nodes 
degree.113 Moreover, the presence of polymorphisms in the promoter of Cdk5 
increases the risk of lung carcinoma in a specific Korean population.111 In 
addiction, the overexpression of Cdk5 caused by gene amplification in lung 
cells may synergize the signaling pathway of epithelial growth factor 
receptor.112  
In mantle cell lymphoma, that is a subtype of B cell lymphoma, it has been 
observed a reduction in methylation of the Cdk5 gene, and this is linked to an 
increasing in Cdk5 mRNA levels.114 Although the link between Cdk5 and the 
mechanism of generation of this tumor remains unknown, the hypothesis that 
Cdk5 may control cell cycle or DNA repair seems to be an interesting scenario 
in which to investigate the role of Cdk5. Altogether, these studies suggest that 
Cdk5 can control the cell cycle via the canonical pathway that involves p35 
binding and a key substrates phosphorylation. Nevertheless, also non-
canonical mechanisms of Cdk5 role that include the binding of cyclins, such 
as cyclin G1and cyclin I, can be important. In addiction, important effects not 
related to the Cdk5 kinase activity can be involved, and in those cases, 
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protein–protein interactions with the kinase can contribute to control the cell 
cycle, suggesting the possibility that Cdk5 functions as a scaffold protein. 
  
	  	  
	  	   27	  
1.3 – MicroRNA 
In the last 20 years, investigators clarify that elements of genome traditionally ! 
considered nonfunctional have a gene regulatory capacity. 
MicroRNAs were initially discovered in 1993 as negative regulators of lin-14 
gene expression in the nematode !Caenorhabditis elegans (C. elegans).115 Then, 
it has been demonstrated that these essential !parts of the uncoding genome 
play a key role in gene regulation in several important processes in different 
species, including vertebrates116 (a list of miRNA databases is reported in 
Table 1.4117 ).  
Table 1.4 – miRNA databases. From Iorio, M.V. and Croce C.M., MicroRNA dysregulation in 
cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 
(2012) 
 
 
MicroRNAs are transcribed by RNA polymerase II as long primary 
transcripts having hairpin structures (pri-microRNAs), and processed into the 
nucleus into pre-microRNAs of 70–100 nts by RNAse III Drosha.118 Drosha is a 
highly conserved protein of 160 kDa, which contains two RNAse III domains 
and one binding domain for double-strand RNA.  
Drosha forms a giant complex called Microprocessor, that is 500 kDa in 
Drosophila melanogaster (D. melanogaster) and 650 kDa in Homo sapiens. 
Microprocessor contains a protein called Pasha in C. elegans and D. 
melanogaster, also known as the co-factor Di George syndrome critical region 
8 (DGCR8) in vertebrates. 
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An alternative biogenesis pathway of miRNA has been discovered among 
diverse nematodes, drosophila and mammals and its name is miRtron 
pathway. In this pathway the regulatory RNAs get processed to form pre-
miRs by the splicing machinery lacking Drosha-mediated cleavage. 119-121 
The precursor molecules are exported to the cytoplasm by an Exportin 5-
mediated mechanism122 and processed by the complex RNAse III 
Dicer/transactivating response RNA- binding protein (TRBP), which 
generates a dsRNA approximately 22 nts long, called miRNA/miRNA*. 
miRNA/miRNA* contain the mature miRNA guide and its complementary 
strand, the miRNA*, known also as the passenger strand (star miRNA; many 
publications distinguish the two strands on the bases of the direction of the 
functional miRNA, named one strand miR-3p (from the 3' arm) and the other 
miR-5p (from the 5' arm). Based on the thermodynamic stability, the guide 
strand or mature miRNA is selected for entry into an RNA-induced silencing 
complex (RISC), whereas the miRNA* is typically subjected to degradation.123 
miRNA* was initially thought to be an inactive and carrier strand, instead 
more recent evidence highlight that it is not a simply non-functional 
bioproduct of miRNA biogenesis, but it may play significant biological 
roles.124 
Dicer is a very large enzyme (≈200 kDa), highly conserved among the species. 
It contains different domains: two RNAse III catalytic domains, a double 
strand RNA-binding domain (dsRBD), one PAZ domain, which binds the 3’-
end of small RNAs, and other domains with RNA-helicasic and ATPasic 
activity. Dicer binds the pre-miRNA, recognizing its double strand region. 
Many other different proteins are involved in this binding: R2D2 e FMR1 
(fragile X mental retardation syndrome 1 homolog) in D. melanogaster, RDE-
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4 (RNA interference; RNAi defective 4) in C. elegans, and members of the 
Argonaut family in other species. Argonaute proteins (AGO 1– AGO 4; AGO1 
and 2 are the most extensively studied) have a key role in miRNA biogenesis, 
miRNA effector functions and maturation.123 These proteins stabilize the 
complex Dicer-miRNA, but they are not required for the endonucleasic 
activity of Dicer. In particular, in mammalians the Argonaut 2 (AGO2) protein 
complex has RNAse H activity and generates an intermediate product, named 
AGO2-cleaved precursor miRNA (ac-pre-miRNA125).  
When the processing steps were completed, the mature single stranded 
miRNA loaded into the Argonaute proteins in the RISC complex, guides RISC 
to the target mRNAs leading to mRNA degradation or repression of 
translation (Fig. 1.3).126,127 
	  	  
	  	   30	  
 
Fig. 1.3 – Biogenesis and mechanisms of action: an overview. From Iorio, M.V. and Croce 
C.M., MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A 
comprehensive review. EMBO Mol Med (2012) 
 
The specificity of miRNA targeting is due to Watson–Crick complementarities 
between its seed region, positions 2 – 8 from the 5′ miRNA, with the 3′ 
untranslated region (UTR) of their target mRNAs.123 When miRNA and its 
mRNA target have perfect complementarity, the RISC induces mRNA 
degradation. If an imperfect miRNA/mRNA target pairing happen, 
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translation into a protein is blocked.123 Beside these two mechanisms, there is 
a site-specific cleavage process, usually defined as RNAi and restricted to 
miRNAs with a near-perfect or perfect match to the target mRNA. This 
process is exclusively Ago2 dependent and it is a very rare event in mammals. 
However, the exact process through which translation can be impaired by 
miRNAs is still debated. In any case, when miRNAs bind the 3’ UTR of the 
target mRNAs, the net result is a reduction in the protein quantities encoded 
by the mRNA targets.117 Considering the different rules that regulate the 
microRNA/mRNA target interaction, it is not surprising that each miRNA 
could potentially target a large number of genes (roughly 500 for each miRNA 
family). About 60% of the mRNAs have evolutionarily conserved sequences 
that are in silico predicted to interact with miRNAs.128-130 Bioinformatical 
predictions show that the 3′ UTR of the mRNA of a single gene is commonly 
targeted by several different miRNAs.131 (Table 1.5 reported a list of 
bioinformatical tools for miRNA target prediction). A lot of these predictions 
have been validated experimentally, indicating that miRNAs could cooperate 
to regulate gene expression.132 
Table 1.5 – Computational tools for miRNA target prediction. From Iorio, M.V. and Croce 
C.M., MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A 
comprehensive review. EMBO Mol Med (2012) 
 
Beyond the canonical mechanisms of miRNA gene expression modulation 
through 3′ UTR interactions, other miRNA-mediated mechanisms of mRNA 
expression regulation are rising in the last years133-137. Indeed, it has been 
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demonstrated that some miRNAs can bind the 5′ UTR or the open reading 
frame of the mRNAs of the target genes and, in some cases, they activate 
rather than inhibit gene expression.133,134 Moreover, Carlo Croce’s group has 
shown that miRNAs can directly bind to ribonucleoproteins in a seed 
sequence and in a RISC-independent way, preventing the bind of these 
proteins to their mRNA targets (decoy activity) (Fig. 1.3).137,138 Three studies 
have also shown that miRNAs can modulate gene expression at the 
transcriptional level through direct bind to the DNA.135,137,139  
All these data highlight the complexity of regulation of gene expression by 
miRNAs. 
 
1.3.1 – miRNA and cancer 
 
MiRNAs have been demonstrated to control a large variety of biological 
processes, including proliferation, development, apoptosis, hematopoiesis, 
differentiation and metabolism.140 Nowadays more than 880 known 
mammalian miRNA genes that may encode a mature miRNA are estimated to 
exist. They regulate the expression of about 30% of gene transcripts.141-143 
Many researcher groups have shown that the disruption of miRNA 
regulatory networks is linked with several diseases, including cancer, and is 
implicated in the initiation and progression of a variety human tumors.144  
MiRNAs can act as both tumor suppressors and oncogenes to inhibit the 
expression of cancer-related target genes145. Thus, human cancers are 
characterized by abnormal miRNA expression pattern. Despite miRNAs have 
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been largely studied in recent years, the molecular mechanisms by which 
miRNAs regulate gene expression are not fully understood and their role in 
tumorigenesis remain still largely undetermined. 
 
1.3.2 – Role of miRNAs in the hallmarks of human cancer  
 
The first paper reporting abnormalities in miRNA expression in cancer cells 
focused on deletion or downregulation of mir-15a–mir-16-1 cluster in B cells of 
patients with chronic lymphocytic leukaemia (CLL)146; after that, other studies 
demonstrated that tumor tissues in patients showed distinctive miRNA 
expression signatures.147 Genome-wide profiling highlighted that these 
miRNA expression signatures allowed to discriminate different types of 
cancer with high accuracy and to identify the tissue of origin of poorly 
differentiated cancers. Despite, mRNA profiles were highly inaccurate 
indicators of the type of cancer or tissue.147 
Nowadays, it is well known that selected groups of distinct miRNAs were 
concurrently and commonly down-regulated or up-regulated in distinct types 
of human cancers and were generally associated with well defined 
cytogenetic abnormalities.148 Indeed, miR-17 and miR-21 were discovered to 
be consistently up-regulated in stomach, prostate, colon, pancreatic and lung 
cancer and miR-155 was shown to be up-regulated in lung, colon, breast 
tumor148; whereas, miR-29 was identified to be down-regulated in acute 
myeloid leukaemia (AML), rhabdomyosarcom, CLL, lung, 
cholangiocarcinoma, liver, mantle cell lymphoma and breast cancer.149-154 
Moreover, miR-15a–miR16-1 was discovered to be down-regulated in CLL, 
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pituitary adenomas and prostate155,156, and let-7 family members were found 
to be down-regulated in colon, ovarian, lung, breast, and stomach cancer122,157-
160. These evidence suggested that up-regulated miRNAs might act as 
oncogenes and down-regulated miRNAs could act as tumor suppressors (Fig. 
1.4). Consequently, it was hypothesized that genes that encode for miRNAs 
can be subject to genomic alterations as well as the coding genes involved in 
cancer. For example, amplification or translocations can lead to up-regulation 
of miRNA expression, whereas insertions, deletions or mutations can lead to 
the miRNA loss of function (Fig. 1.4). 
 
 
Fig. 1.4 – MicroRNAs as oncogenes or tumour suppressor genes. From Iorio, M.V. and Croce 
C.M., MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A 
comprehensive review. EMBO Mol Med (2012) 
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Consistent with this postulate, Carlo Croce’s group found that the genes 
encoding miRNAs are in fact generally located inside or close to fragile sites 
and in minimal regions of loss of amplification, in minimal regions of 
heterozygosity and in common breakpoints associated with cancer.161 For 
examples, The mir-17-92 cluster, which includes six miRNAs (mir-17, mir-18a, 
mir-19a, mir-19b-1, mir-20a and mir-92-1), is situated in an 800 base-pair region 
of the non-coding gene C13orf25, a region commonly amplified in 
lymphomas. The miR-17-92 cluster has commonly been found overexpressed 
in hematological malignancies or in solid tumors.151,153 Instead, the mir-15a–
mir-16-1 cluster, that is situated in the chromosome 13q14 region (between 
exon 2 and exon 5 of the non-coding gene LEU2), is usually down-regulated 
in patients with CLL because this genomic region is deleted.146,162 
In addition to structural genetic alterations, miRNA genes could be silenced 
by DNA promoter histone hypoacetylation and/or hypermethylation; it has 
been described in hematological malignancies and in solid tumors.163-165 Saito 
et al. first demonstrated that miR-127 down-regulation was due to promoter 
hypermethylation in human bladder cancer. After hypomethylating agents 
treatment, miR-127 is re-expressed, correlating with the oncogene B-cell 
lymphoma protein-6 (BCL-6) down-regulation, which is a validated target of 
miR-127.166 
Aberrant expression of miRNA in cancer might also result from downstream 
miRNA processing (FIG. 2). Kumar et al. demonstrated that miRNA-
processing machinery knockdown by short hairpin RNAs against Drosha and 
Dicer, and the consequent global depletion of miRNAs, stimulates 
tumorigenesis and cell transformation in vivo.167 Moreover, the conditional 
loss of Dicer1 in the lung tissues in a Kras mouse model promotes lung tumors 
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development.168 The loss of Drosha and Dicer has also been inversely linked 
with outcome in the ovarian epithelium cancer.169 
Finally, miRNA expression deregulation can be due to a decreased or 
increased transcription from their respective miRNA genes through aberrant 
transcription factor activity. For example, the miR-34a, miR-34b and miR-34c 
miRNA family was found to be directly induced by the tumor suppressor p53 
and it was proposed that some of the p53 effects might be mediated by the 
transcriptional activation of miRNAs. Chromatin immunoprecipitation 
experiments demonstrated the p53 binding to the promoter of miR-34.170,171 
Recent work also showed that the oncoprotein MYC negatively regulates 
transcription of some tumor suppressor miRNAs, such as let-7 (let-7a, let-7c, 
let-7d, let-7f1 and let-7g) and mir-29 family members (mir-29a, mir-29b and mir-
29c). Functionally, it was discovered that MYC-induced repression of 
miRNAs is involved into lymphomagenesis; indeed the restoration of the 
silenced miRNAs decreases the lymphoma cells tumorigenic potential.172 
Expression profiling of miRNAs showed that the miRNA signature is 
associated with tumor diagnosis, classification and progression, as well as 
response to treatment and prognosis.149,173 Anyway, the interaction between 
miRNAs and the classical tumor suppressors and oncogenes is only now 
beginning to be elucidated. 
 
1.3.3 – miR26a and cancer 
 
MiR-26a, together with miR-26b, belongs to the miR-26 family. The role of 
miR-26a in cancer cells is controversial nowadays. Some studies have shown 
	  	  
	  	   37	  
that miR-26a is down-regulated and act as tumor suppressor in breast 
cancer174, hepatocellular carcinoma175, nasopharyngeal carcinoma176, gastric 
cancer177, prostate carcinoma178 and bladder cancer179. Other studies have 
demonstrated to act as an oncogene in cholangiocarcinoma180, lung cancer181 
and glioma182.  
Until now, the role of miR-26a in DLBCL was undefined. 
 
1.3.4 – Rational for targeting miRNA 
 
As miRNAs regulate several different pathways and coordinate integrated 
responses in normal healthy tissues and cells, it’s reasonable to think that they 
also play a key roles in orchestrate cancerous networks. This characteristic 
makes them excellent candidates for innovative molecular-targeting 
treatments.  
The rationale for utilizing miRNAs as drugs against tumor is based on two 
main findings: that the expression of miRNAs is deregulated in tumor cells 
compared with normal cells, and that the targeting of miRNA expression can 
change tumor phenotype.146,158,183,184 Indeed, if normal miRNA program is 
restored in the neoplastic cells, the cell connectivity map might be rewired 
and cancer phenotypes might be reversed. The therapeutic strategy aims to 
rescue homeostasis in cancer cells by modifying miRNA expression might be 
more successful and comprehensive than targeting single proteins or genes, 
as there are only some miRNAs deregulated in tumor, compared with the 
high number of perturbations of the proteome and transcriptome in 
neoplastic cells.  
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1.3.5 – miRNA-based therapeutic strategies  
 
Two main strategies can be used to target miRNA expression in tumor. Direct 
strategies implicate the use of virus-based constructs or oligonucleotides to 
either restore the loss of expression of a tumor suppressor miRNA or to block 
the expression of an oncogenic miRNA. The indirect strategy implicates the 
use of drugs to regulate miRNA expression by targeting their processing or 
transcription. (Fig. 1.5) 
 
 
Fig. 1.5 – Blocking oncogenic microRNAs (miRNAs) could be achieved by using a| small 
RNA inhibitors, b| antisense oligonucleotides, c| miR-mask, and d| miRNA sponges. 
Restoring downregulated miRNA expression could be achieved by using e| synthetic 
miRNAs (miRNA mimics) and f| viral constructs containing genes coding for miRNAs. EF1α, 
elongation factor 1 α; GFP, green fluorescent protein; ITR, inverted terminal repeats; ORF, 
open reading frame; RISC, RNA-induced silencing complex. From Garzon R., et al. Targeting 
microRNA in cancer: rational, strategies and challenges. (2010) 
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To block oncogenic microRNAs (miRNAs) small RNA inhibitors, antisense 
oligonucleotides, miR-mask, and miRNA sponges can be used (Fig. 1.5).185-189 
Small-molecule miRNA inhibitors might modulate miRNA expression at the 
transcriptional level189; antisense oligonucleotides might bind to the target 
miRNAs according to the Watson–Crick complementarities and promote 
either duplex formation or degradation; miR-mask oligonucleotides are 
synthetic oligonucleotides complementary to the 3’ UTR of the target mRNA 
that compete with endogenous miRNAs for its target.190 Hence, the miR-mask 
can block oncogenic miRNA activities at the target level and promote 
translation of target mRNAs. The miRNA sponges are oligonucleotide 
constructs with multiple complementary miRNA binding sites (in tandem) to 
the target miRNA.191 After the introduction into the cell, sponges will ‘soak 
up’ endogenous miRNAs, diminishing the expression levels of the oncogenic 
miRNA. 
To rescue down-regulated miRNA expression synthetic miRNAs (miRNA 
mimics) or viral constructs containing genes coding for miRNAs, such as the 
adenovirus-associated vectors (AAV) can be used.192,193 
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A significant proportion of patients with DLBCL are refractory to first-line 
chemotherapy or relapsing after autologous transplantation. Thus, novel 
targets for innovative treatments are needed. 
 
In preliminary experiments, we observed that Cdk5 and p35 protein are 
overexpressed and that miR26a is down-regulated in several DLBCL cell lines 
compared to B lymphocytes from healthy donors. 
 
We hypothesize that Cdk5 plays a key role in tumor growth of DLBCL by 
promoting cell proliferation and by inducing resistance to apoptotic stimuli in 
neoplastic cells, and that the expression of its activator p35 is directly 
regulated by miR26a. Therefore, Cdk5 may be a new potential target for 
treatment of DLBCL. 
This study provides a better understanding of DLBCL pathogenesis, 
important to develop new opportunity of effective treatment. 
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METHODS 
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3.1 – REAGENTS  
Recombinant sTRAIL (KillerTRAIL™) was purchased from Alexis 
Corporation (Lausen, Switzerland, EU); Bortezomib (Velcade; formerly PS-
341) was purchased from Selleck Chemicals (Houston, TX, USA) and 
dissolved in DMSO. 
 
3.2 – CELL LINES 
SU-DHL-4, SU-DHL-6, SU-DHL-16, (Germinal center B-cell like diffuse large 
B-cell lymphoma), SU-DHL-2, SU-DHL-8, and RCK-8 (Activated B-cell like 
diffuse large B-cell lymphoma) cell lines were purchased from the German 
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany, EU). Cell lines were cultured in RPMI-1640 supplemented with 
20% fetal bovine serum (FBS) and periodically tested for mycoplasma 
contamination. B lymphocytes derived from human blood samples. B cells 
were isolated by negative selection using RosetteSep® B cell enrichment 
cocktail (Stem Cell Technologies, Vancouver, Canada) according to the 
manufacturer's instructions. B cell purity was assessed by flow cytometry by 
staining for mature B cells (CD20), T cells (CD3) and monocytes (CD14) using 
fluorescently-labeled monoclonal antibodies, all from BD Biosciences (Oxford, 
UK). Flow cytometry experiments were conducted with FACSCalibur™ 
(Becton-Dickinson, San Jose, CA, USA) using BD CellQuest software version 
3.3 (BD). The data were analyzed using FlowJo 7.3.5 software version for 
Windows (Tree Star, Inc. Ashland, OR). 
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3.3 – GENERATION OF LOSS- AND GAIN-OF-FUNCTION 
CDK5/P35 OR MIR-26A STABLE DLBCL CELL LINES 
Lentiviral CDK5 short hairpin RNA (shRNA) (#66 and #67) and p35-shRNA 
(#217 and #218) were obtained from The RNAi Consortium 
(http://www.broadinstitute.org/rnai/trc). A scramble shRNA was used as a 
control. Lentiviral particles were generated using a three-plasmid system, as 
previously described194 For p35-expressing lentiviral particles, a p35-
expressing vector containing the human CDS p35 complementary DNA 
(NM_003885.2) was cloned in a lentiviral plasmids. DLBCL cells were 
transduced with lentiviral particles and polybrene at 8 µg/mL (Sigma-
Aldrich, St. Louis, MO), followed by puromycin selection at 48 hours after the 
transduction. Efficiency of knockdown or overexpression was validated by 
immunoblotting and/or qRT-PCR. 
 
3.4 – VIRAL INFECTION OF DLBCL CELL LINES 
SU-DHL-4, SU-DHL-8 and SU-DHL-16 (0.4 × 106 per milliliter) were 
resuspended in lentivirus containing supernatant in the presence of polybrene 
(8 µg/ml) in a six-well plate. Plates were centrifuged at 1,000 g for 90 min. 
After centrifugation, cells were washed, resuspended in fresh culture 
medium, and incubated at 37°C in a CO2 incubator. Three days after infection, 
cells were washed in phosphate-buffered saline (PBS) and resuspended in 
FACS buffer (PBS with 5% FCS). Gene transduction efficiency was 
determined by cytofluorimetric analysis using the BD FACSCalibur™ flow 
cytometer (BD Biosciences, San Jose, CA, USA) and analysed as previously 
described. 
	  	  
	  	   45	  
3.5 – APOPTOSIS ASSAYS 
The Annexin-V–fluorescein isothiocyanate (FITC) assay (Immunostep, 
Salamanca, SP, EU) was used to detect cell death by apoptosis or necrosis and 
was carried out according to the manufacturer’s instructions. SU-DHL-8 cells 
were cultured at 0,4/ml in RPMI 20% FBS and treated with 2.5 or 5 ng/ml 
TRAIL. In order to detect apoptotic cells, cells were recovered after 24h, 
double stained and analysed on a FACSCalibur flow cytometry system 
(Becton-Dickinson, San Jose, CA, USA) as previously described. 
3.6 – CELL CYCLE ANALYSIS 
Cells (1 x 106) were cultured in the absence or presence of TRAIL for 8, 24, 48 
and 72 hours. All of the cells were washed with PBS and fixed in 70% ethanol 
and kept at 4°C prior to DNA staining with 2.5 µg/ml PI (Calbiochem, 
Darmstadt, Germany) in the presence of 12.5 µg/ml RNAse (Sigma-tau, 
Rome, Italy). The number of cells at each stage of the cell cycle was measured 
using a FACSCalibur flow cytometry system (BD). The histograms were 
analysed using the FlowJo 7.3.5 software version for Windows. 
 
3.7 – WESTERN BLOT ANALYSIS 
Cell samples were homogenized in NP-40 lysis buffer (1% NP-40, 20 mM Tris-
HCl pH 8, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM sodium 
orthovanadate, 10 µg/mL aprotinin, 10 µg/mL leupeptin). Protein 
concentrations were determined by using BCA (bicinchoninic acid) Protein 
Assay. Cell lysates were resolved by electrophoresis on a 10% polyacrylamide 
gel and transferred to nitrocellulose membranes. Immunocomplexes were 
visualized using an enhanced chemiluminescence Western blotting detection 
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system (Amersham Biosciences, Milano, Italy, EU). Blotting analysis was 
performed using antibodies against the following proteins: CDK5 (1:1000), 
p35 (1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), GAPDH 
(1:1000) (Cell signaling, Danvers, MA, USA), actin (Sigma-tau, Rome, Italy), 
STAT3 (1:1000) and pSTAT3 (1:1000) (Cell signaling, Danvers, MA, USA). 
HRP- conjugated secondary antibodies against mouse or rabbit were used to 
detect each protein line. 
3.8 – RNA EXTRACTION AND REAL-TIME PCR 
Total RNA was extracted using Purezol reagent (Bio-Rad, US) following the 
manufacturer's instructions. Two micrograms of total RNA was used for 
cDNA synthesis with Oligo d(T) primer. Real-time PCR was carried out for 
detection of CDK5, p35 and miR-26a mRNA level on an Applied Biosystems 
7900HT Fast Real-Time PCR. PCR reactions were run in duplicate for three 
independent experiments. The mRNA levels were referred to β-actin, 18s or 
GAPDH as housekeeping genes and analysed using the ΔΔCt method. 
 
3.9 – LUCIFERASE ASSAY 
We performed luciferase reporter experiments in the HEK293T cell line. 3' 
UTR segment of p35 predicted to interact specifically with miR-26a were 
subcloned by standard procedures into the psiCHECK-2 vector (Promega, 
Madison, WI, USA) immediately downstream of the stop codon of the renilla 
gene using the primers p35–5′ (5′-GAGGCTGCTTCGGATGGAGGGA-3′), 
p35–3′ (5′-TAAGATTTAACATCATCATATT-3′). Seed sequence mutagenesis 
was performed as described by the manufacturer (Agilent Technologies, 
Santa Clara, CA, USA). We made short constructs (80–100 bases), 
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encompassing wild-type or mutated (six point mutations) seed sequences, in 
order to separately analyse the functional role of each seed. The seed 
sequences are indicated in figure 4.12. Using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA, USA), cells were transfected with psiCHECK-2-3'UTR plasmid 
and plasmids containing non-targeting RNA control or miR-26a. Renilla 
luciferase signal is normalized to the firefly Luciferase signal. At 48 h after 
transfection, cells were lysed and luciferase activity was measured by Synergy 
H4 Hybrid Multi-Mode Microplate Reader (BioTek Instruments, Winooski, 
VT, USA). 
 
3.10 – IN VIVO TUMOR GROWTH OF ENGINEERED             
SU-DHL-8 CELL LINES IN NON-OBESE DIABETIC/SEVERE 
COMBINED IMMUNODEFICIENT (NOD/SCID) MICE.  
Six- to eight-week-old NOD/SCID mice with body weights of 20 to 25 g were 
purchased from Charles River (Milano, Italy, EU) and used to generate 
xenografts of SU-DHL-8 cells. The animal experiments were performed 
according to Italian laws (D.L. 116/92 and following additions) and approved 
by the institutional Ethical Committee for Animal Experimentation. The 
engineered tumor cell lines were injected subcutaneously (SC). The cells were 
inoculated (10 × 106 cells/mouse) into the left flank of each mouse.  
The endpoint of the experiment was tumor weight. The tumor cells were 
fluorescent, thus the tumors were measured with IVIS in vivo imaging system 
(PerkinElmer, Waltham, USA), in addiction to caliper. After caliper 
measurements, their volumes were calculated using the formula: (a × b2)/2, 
where a and b represented the longest and shortest diameters, respectively. 
Mice were monitored three times weekly and were killed by cervical 
dislocation when they showed signs of terminal illness, including hind leg 
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paralysis, inability to eat or drink, and/or moribund. Each experiment was 
performed on at least two separate occasions, using five mice per experiment.  
 
3.11 – HISTOLOGICAL ANALYSIS AND 
IMMUNOHISTOCHEMISTRY 
Sections (2  µm) from formalin-fixed, paraffin-embedded tumor nodules were 
stained with hematoxylin and eosin or processed for tumor necrosis analysis. 
Tumor necrosis was detected by terminal deoxynucleotidyl transferase dUTP 
nick end labeling staining (TUNEL) (Roche, Milano, Italy) according to the 
manufacturer’s instructions. The sections were examined using a light 
microscope (IX51; Olympus, Tokyo, Japan). Image analysis was performed 
using open source ImageJ software (http://rsb.info.nih.gov/ij/). 
 
3.12 – BIOINFORMATICS 
To identify the potential miR-26a targets the algorithms miRanda 
(http://www.microrna.org), TargetScan (http://www.targetscan.org), and 
PicTar (http://pictar.mdc-berlin.de/) were used. 
 
3.13 – STATISTICAL ANALYSIS 
Statistical analyses were performed using Prism 7.2.5 (GraphPad Software, 
Inc., La Jolla, CA, USA). To test the probability of significant differences 
between samples and their controls, a two-way analysis of variance was 
employed, and individual group comparisons were evaluated using the 
Bonferroni post-test. Terminal deoxynucleotidyl transferase dUTP nick end 
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labeling data were analysed using one-way analysis of variance, an individual 
group comparisons were evaluated using the Bonferroni post-test. Differences 
were considered significant at the level of P≤0.05. Unpaired Student’s t test, 
paired Student’s t test were also used. Data are represented as mean ± SEM 
unless otherwise stated.  
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4. RESULTS 
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4.1 – CDK5 AND ITS ACTIVATOR P35 ARE OVEREXPRESSED 
IN LYMPHOMA CELL LINES AND REGULATE THE 
PHOSPHORYLATION AND ACTIVITY OF STAT3 
Previous reports have shown that several solid tumors present an over 
activation of CDK5 that correlates with the progression of the disease. First of 
all, we investigated if CDK5 could have a role in hematologic malignancies. 
By using immunoblotting, we found that CDK5 and its activator p35 are 
overexpressed in several lymphoma and leukemia cell lines compared to B 
lymphocytes (Figure 4.1 A, B and C). 
 
  
Fig. 4.1 A, B and C – CDK5 and p35 are overexpressed in Lymphoma and Leukemia cell 
lines. (A) Representative immunoblots of CDK5 and p35 protein expression in primary B 
lymphocytes, B-cell chronic lymphocytic leukemia (B-CLL), Hodgkin lymphoma (HL) and 
Burkitt's lymphoma (BL) cell lines. Densitometric analysis of (B) p35 and (C) CDK5 protein 
levels. Relative concentrations are shown as a ratio normalized to β-actin. The value in the 
control sample (B cells) was arbitrarily defined as 1. Results are representative of 3 
independent experiments. Significant differences indicated by: *p < 0.05, and °p < 0.01, #p< 
0.001 
 
 
We focused on DLBCL that is the most common form of non-Hodgkin 
lymphoma and we found that Cdk5 and p35 proteins were overexpressed in 
all the DLBCL cell lines we analysed (figure 4.2 A, B and C). 
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Fig. 4.2 A, B and C – CDK5 and p35 are overexpressed in DLBCL cell lines. (A) 
Representative immunoblot for CDK5 and p35 proteins in B lymphocytes and DLBCL cell 
lines. Densitometric analysis of (B) p35 and (C) CDK5 proteins normalized to β-actin. 
Significant differences indicated by: *p < 0.05, and °p < 0.01, #p< 0.001.   
 
Moreover, we measured the level of STAT3 phosphorylation, a known target 
of CDK557, at the Serine 727 (S727) in all DLBCL cell lines we collected. By 
using CDK5-specific shRNAs, we confirmed that phosphorylation level at 
S727 of STAT3 was dependent on the expression of CDK5 in DLBCL cell lines 
(Figure 4.3 A, B). As expected, all DLBCL cell lines showed a higher level of 
phosphorylation (Figure 4.3 C and D).  
These results indicate that there is an overexpression of CDK5 and its 
activator p35 in DLBCL cells. 
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Fig. 4.3 A, B, C and D – (A) Immunoblot of STAT3 S727 phosphorylation level in SU-DHL-8 
expressing CDK5-specific shRNAs. (B) Densitometric analysis of normalized pSTAT3 to total 
STAT3. (C) STAT3 S727 phosphorylation level in B lymphocytes and DLBCL cell lines. (D) 
Densitometric analysis of pSTAT3 normalized to total STAT3 and β-actin. The value in the 
control sample (B lymphocytes) was arbitrarily defined as 1. Results are representative of 3 
independent experiments. Significant differences indicated by: *p < 0.05, and °p < 0.01, #p< 
0.001. 
 
 
4.2 – CDK5 ACTIVITY IN DLBCL CELL LINES IMPAIRS 
PROLIFERATION 
To dissect the functional relevance of CDK5 expression and activity in 
modulating DLBCL cell malignant phenotypes, we studied the effects of 
CDK5 and p35 loss-of-function and p35 gain-of-function on proliferation and 
in different DLBCL cell lines. We knocked down CDK5 and p35 using two 
different lentiviral shRNAs for each gene. We used one Activated B-cell like 
(ABC) DLBCL cell line, SU-DHL-8, and one Germinal Center B-Cell like 
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(GCB) DLBCL cell line, SU-DHL-4, both expressing high level of CDK5 and 
p35. The silencing efficiency was confirmed by qRT-PCR (Figure 4.4 A and B) 
and the cell growth was monitored at various time points (24, 48, 72 and 96 
hours). Stable expression of p35-specific shRNAs inhibited SU-DHL-8 cell 
proliferation by 40% (average between two shRNAs) (P< 0.001) (Figure 4.4 C). 
 
Fig. 4.4 – p35 affects proliferation rate of DLBCL cells. (A) CDK5 and (B) p35 RNA levels in 
SU-DHL-8 expressing CDK5 or p35-specific shRNAs. (C) Down-regulation of p35 with two 
different shRNAs significantly  inhibited cell proliferation of SU-DHL-8 cells. Results are 
representative of 3 independent experiments. Significant differences indicated by: *p < 0.05, 
and °p < 0.01, #p< 0.001. 
 
Similar effects on cell proliferation were observed using CDK5-specific 
shRNAs in SU-DHL-8 (Figure 4.5 A). Moreover, we created two SU-DHL-8 
sub-lines stably expressing the recombinant mouse CDK5 together with each 
hCDK5-specific shRNAs (#6 and #7). As showed in figure 4.5 B and 4.5 C the 
expression of exogenous mCDK5 reverted almost completely the effect on the 
proliferation induced by the hCDK5-specific shRNAs. Similar effects on cell 
proliferation of CDK5-specific shRNAs were found in SU-DHL-4 cell line 
(Figure 4.5 D). 
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Fig. 4.5 – CDK5 impairs proliferation of DLBCL cells. (A) Down-regulation of CDK5 with 
two different shRNAs significantly  inhibited cell proliferation of SU-DHL-8 cells, while (B 
and C) concomitant expression of mouse CDK5 increased cell proliferation of SU-DHL-8 cells 
compared to control level. (D) Down-regulation of CDK5 with two different shRNAs 
significantly  inhibited cell proliferation of SU-DHL-4 cells. Results are representative of 3 
independent experiments. Significant differences indicated by: *p < 0.05, and °p < 0.01, #p< 
0.001. 
 
 
To further strength this result, we performed gain-of-function experiment, 
expressing the p35 coding DNA sequence (CDS) in the SU-DHL-16 cell line 
that showed the lowest level of p35 expression (Figure 4.2 A and B) and 
CDK5 activity (Figure 4.3 C and D). p35 over-expression was confirmed by 
western blotting and qRT-PCR (Figure 4.6 A and B). Consistently with 
previous results, stable expression of recombinant p35 increased cell 
proliferation by 37% (P<0.001) (Figure 4.6 C). These results clearly 
demonstrate that CDK5 and its activator p35 regulate proliferation of DLBCL 
cells. 
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Fig. 4.6 – p35 overespression increases proliferation rate of SU-DHL-16 cells. p35 protein 
(A) and mRNA (B)  levels in SU-DHL-16 expressing recombinant human CDS p35. (C) Up-
regulation of p35 significantly increased proliferation of SU-DHL-16 cells. Results are 
representative of 3 independent experiments. Significant differences indicated by: *p < 0.05, 
and °p < 0.01, #p< 0.001. 
 
 
 
4.3 – CDK5 ACTIVITY IS REQUIRED TO PROTECT DLBCL 
CELLS FROM APOPTOSIS  
We asked whether CDK5 has a biological role enhancing lymphoma cells 
survival similar to what has been reported in neurons 195 and in podocytes 76. 
SUDHL8 expressing p35-specific shRNAs did not show a significant 
difference of apoptotic cells compared to cells expressing scrambled sequence 
(Figure 4.7 A and B). We also investigated whether p35 silencing may 
enhance sensitivity to pro-apoptotic agents, such as sTRAIL, and found that 
p35-knockdown SU-DHL-8 cells showed a significantly higher cytotoxicity 
when exposed to sTRAIL, compared to scrambled-transduced cells (Figure 4.7 
A and B). 
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Fig. 4.7 – p35 regulates apoptotic rate of DLBCL cells. (A and B) Down-regulation of p35 in 
SU-DHL-8 significantly increased apoptotic cell number assessed by Annexin-V/PI staining 
in the presence of 5 ng/ml Killer sTRAIL. All data are derived from 3 independent 
experiments with 6 replicates. Significant differences indicated by: *p < 0.05, and °p < 0.01, 
#p< 0.001. 
 
Similarly, cells with reduced CDK5 level did not showed increased apoptotic 
events in the absence of an apoptotic stimulus, but showed an augmented 
sTRAIL–induced apoptosis (Figure 4.8 A and B), even at the higher 
concentration of TRAIL used (Figure 4.8 C). 
A B 
P
ro
pi
di
um
 Io
di
de
 (P
I) 
Annexin-V 
NT sTRAIL 
sh
SC
R
 
sh
p3
5#
7 
sh
p3
5#
8 
NT sTRAIL
0
20
40
60
80
100 shSCR
shp35#7
shp35#8 #
#
C
el
l d
ea
th
 %
	  	  
	  	   58	  
 
Fig. 4.8 – CDK5 activity protects DLBCL cells from apoptosis. (A and B) Down-regulation of 
CDK5 significantly  increased apoptotic cell number in SU-DHL-8 in the presence of 5 ng/ml 
Killer sTRAIL. (C) SU-DHL-8 expressing CDK5 specific shRNA treated with different 
concentrations of apoptotic agent sTRAIL. Results are representative of 3 independent 
experiments. Significant differences indicated by: *p < 0.05, and °p < 0.01, #p< 0.001. 
 
 
CDK5 silencing increases apoptotic events in DLBCL cells.  
 Inhibiting CDK5 activity using chemical compounds further confirmed that 
CDK5 activity is important to protect cells from apoptosis (Figure 4.9 A, B and 
C).  
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Fig. 4.9 – CDK5 inhibitors regulate apoptotic rate of DLBCL cells. Combination of different 
CDK5 inhibitors (A) PURVALANOL, (B) CGP, and (C) Kemp with the apoptotic agent 
sTRAIL. (D) Down-regulation of CDK5 significantly  increased apoptotic cell number in SU-
DHL-4 in the presence of 5 ng/ml Killer sTRAIL. Results are representative of 3 independent 
experiments. Significant differences indicated by: *p < 0.05, and °p < 0.01, #p< 0.001. 
 
Similar results have been obtained also in SU-DHL-4 cell line (Figure 4.10 A 
and B).  
To further strength this result, we measured apoptosis level in SU-DHL-16 
overexpressing p35. Consistently with previous results, we detected 
significant decrease in BTZ–induced apoptosis ratio after p35 overexpression 
(Figure 4.10 C and D). These results strongly suggest that CDK5 activity is 
able to prevent apoptotic events in DLBCL cells. 
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Figure 4.10 – CDK5 regulates apoptotic rate of DLBCL cells. (A and B) Down-regulation of 
CDK5 significantly  increased apoptotic events in SU-DHL-4 in the presence of 2.5 ng/ml 
Killer sTRAIL. (C and D) Up-regulation of p35 significantly decreased apoptotic cell number 
of SU-DHL-16 after treatment with Bortezomib. All data are derived from 3 independent 
experiments with 6 replicates. Significant differences indicated by: *p < 0.05, and °p < 0.01, 
#p< 0.001. 
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4.4 – MIR-26A REPRESSES P35 EXPRESSION 
While we observed a correlation between CDK5 mRNA and protein levels, in 
lymphoma cells we did not observe the same correspondence for p35: 
compared to B lymphocytes, cancer cells showed higher protein level, but 
lower mRNA levels (Figure 4.2 A and 4.11 A and B).  
 
Fig. 4.11 – CDK5 and p35 mRNA are different modulated in DLBCL cells. (A) CDK5 and 
(B) p35 mRNA expression in DLBCL cell lines. 
 
This led us to investigate potential post-transcriptional mechanisms 
regulating p35 expression. To elucidate the regulation of p35, we searched for 
miRNAs that can potentially bind to its 3’–UTR. Bioinformatic analysis 
showed that miR-26a has a putative binding site in the p35 3’–UTR with seed 
sequence located at positions 2061-2067 bp (Figure 4.12 A). To test whether 
p35 was regulated by miR-26a, its precursor (hsa-pre-miR-26a) was expressed 
into SU-DHL-8 cells. Western blotting of whole lysate of cells overexpressing 
hsa-miR-26a showed a decrease of the native p35 protein (Figure 4.12 B and 
C), compared to control. Over-expression efficacy was confirmed by qPCR by 
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measuring the level of the mature miRNA, demonstrating an increased 
expression after transfection at 24 hours (Figure 4.12 D). 
 
Figure 4.12 – miR-26a affects p35 expression. (A) miR-26a and its putative binding sequence 
in the 3’-UTR of p35. In red, the mutant seed sequence (wt, wild type; mt, mutant type). (B) 
Representative immunoblot for p35 in SU-DHL-8 overexpressing miR-26a. (C) Densitometric 
analysis of p35 protein normalized to β-actin. (D) Expression of miR26a in SU-DHL-8 
measured by RT-PCR. The value in the control sample was arbitrarily defined as 1. Results 
are representative of 3 independent experiments. 
 
 
 
To further demonstrate that the observed effect of miR-26a on p35 expression 
was direct by binding to its 3’–UTR, we performed a luciferase experiment. 
We fused the p35 3’–UTR sequence to a luciferase reporter gene. Then, by co-
transfecting the hsa-miR-26a with this vector, we demonstrated that miR-26a 
significantly repressed luciferase activity compared to a non-targeting control. 
Mutagenesis of the seed sequence led to a recovery of the luciferase activity 
(Figure 4.13). Taken together, these results suggest that p35 is a direct target 
of miR-26a in DLBCL cells. 
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Fig. 4.13 – p35 is a direct target of miR-26a. MiR-26a significantly suppressed luciferase 
activity of plasmid carrying the wt but not the mt 3’UTR of p35. Values are normalized to the 
value of control, which is indicated as 100%. Significant differences indicated by: °P <0.01. 
Error bars represent the mean ± SEM. 
 
 
4.5 – MIR-26A MODULATES PROLIFERATION AND CELL 
CYCLE PROGRESSION OF DLBCL CELLS THROUGH P35 
REGULATION 
First, expression level of miR-26a was measured in DLBCL cell lines by qRT-
PCR and normalized against U6 snRNA. MiR-26a was strongly down-
regulated in DLBCL cells compared to B lymphocytes (Figure 4.13 A). Next, 
we investigated the role of miR-26a in lymphoma cells. To this end, we 
examined the effects of hsa-miR-26a lentivirus expression on proliferation rate 
of SU-DHL-8 ABC-DLBCL cells. Transduction efficiency was evaluated by 
qRT-PCR (Figure 4.12 D). Compared to control, hsa-miR-26a expression 
markedly decreased lymphoma cell proliferation by 41% (P<0.01) (Figure 4.13 
B). Moreover, hsa-miR-26a expression substantially augmented sTRAIL–
induced apoptosis of SU-DHL-8 cell line (Figure 4.13 C and D).  
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Fig. 4.14 – miR-26a affects proliferation and apoptosis in DLBCL cell lines. (A) Expression 
levels of miR-26a in DLBCL cell lines. (B) Up-regulation of miR-26a significantly inhibited cell 
proliferation and (C and D) increased the apoptotic rate compared with controls. Mean (± 
SEM) values refer to three independent experiments. Significant differences indicated by: *P < 
0.01, °P < 0.05 and #P < 0.001. 
 
Then, in order to demonstrate that the effect of miR-26a on proliferation and 
apoptosis of DLBCL was mediated by p35 and, consequently, by the 
modulation of CDK5 activity, we generated different new cell lines using 
lentiviral vectors: starting from SU-DHL-8, we created a control line (E.V.), a 
cell line overexpressing miR-26a (miR-26/E.V.) and a cell line overexpressing 
miR-26a together with a vector expressing the human p35 ORF, missing the 
3’–UTR (miR-26/p35). Regulation of p35 expression and miR-26a 
overexpression were confirmed by western blotting and qRT-PCR (Figure 
4.14 A, B and C).  
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Fig. 4.15 – Expression of miR-26a and p35 in SU-DHL-8. (A and B) Immunoblot for p35 in 
SU-DHL-8 overexpressing miR-26a and in SU-DHL-8 overexpressing miR-26a together with 
human p35 missing the 3’–UTR. (B) Densitometric analysis of p35 protein normalized to β-
actin. (C) Transduction efficient of the engineered cell lines. Mean (± SEM) values refer to 
three independent experiments. Significant differences indicated by: *P < 0.01, °P < 0.05 and 
#P < 0.001. 
 
 
Compared to miR-26/E.V. cells, miR-26/p35 clone markedly showed an 
increase on cell proliferation and a decrease on apoptosis, similar to the 
proliferation and apoptosis index detected in E.V. cells (Figure 4.15 A, B and 
C). These data demonstrate that miR-26a regulates proliferation and apoptotic 
event in DLBCL cells and that p35 is an important mediator of these biological 
events.  
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Fig. 4.16 – miR-26a controls proliferation and apoptosis of DLBCL cells through p35 
regulation. (A and B) Concomitant expression of a p35 with a 3’UTR truncated form together 
with miR-26a restored apoptotic rate and (C) cell proliferation rate and to control level 
compared to miR-26a alone. 
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4.6 – MIR-26A MODULATES IN VIVO TUMOR GROWTH OF 
DLBCL THROUGH P35 REGULATION 
SU-DHL-8 cells stably expressing miR-26a (miR-26/E.V.), cells 
overexpressing miR-26a together with a vector expressing the human p35 
missing the 3’–UTR (miR-26/p35) or control vectors (E.V.) were injected 
subcutaneously into nude mice. Palpable tumors formed within 2/3 weeks. 
Tumor volume was monitored for 35 days using a caliper. In addiction, 
because these cells were GFP positive, we also detected tumor growth by IVIS 
in vivo imaging scan, calculated the fluorescence intensity of the tumor 
nodules (Figure 4.16 A). Mice were sacrificed 5 weeks after tumor cell 
implantation. 
The tumors of SU-DHL-8 miR-26/E.V. group were not detectable for almost 
all the time of the experiment, while SU-DHL-8 (miR-26/p35) and SU-DHL-8 
(E.V.) presented an average tumor volume very similar (6/8 cm3; P < 0.01) 
(Figure 4.16 A, B and C). 
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Fig. 4.17 – MiR-26a regulates in vivo tumor growth of DLBCL through p35 regulation. miR-
26a overexpression suppressed tumor growth in subcutaneous implantation mouse models of 
SU-DHL-8 cells. (A) In vivo fluorescente images (ventral) of three representative mice 
challenged with DLBCL cells. (B) Tumor growth curves of subcutaneous implantation models 
of DLBCL are shown. (C) Tumor volumes were monitored until 5 weeks after the challenge. 
Number of mice per group: 5. Mean (± SEM) values refer to three independent experiments. 
Significant differences indicated by: *P < 0.01, °P < 0.05 and #P < 0.001 in comparison with 
single treatments. 
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Intra-tumoral apoptosis was detected by using tunnel staining and we 
confirmed an increased level of apoptosis in the group of mice injected with 
SU-DHL-8 miR-26/E.V. while SU-DHL-8 miR-26/p35 and SU-DHL-8 E.V. 
presented similar level of cellular dead (Figure 4.17 A and B).  
 
 
 
Fig 4.18 – miR-26a in vivo promotes tumor necrosis by targeting p35. (A and B) DLBCL 
tumor sections stained with H&E (upper panel). Apoptotic tumor cells were visualized 
(lower panels) and quantified using the TUNEL assay.  
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5. DISCUSSION AND 
CONCLUSIONS 
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Diffuse Large B-cell lymphoma (DLBCL) is the most common types of 
aggressive lymphoma worldwide.1 The standard of care is the 
immunochemotherapy R-CHOP, but the chemorefractory and relapsed after 
treatment patients (approximatively 30-40%) represent an unmet medical 
need, requiring novel targets for innovative treatments.196 One potential target 
is cyclin-dependent kinase 5 (CDK5), a serine/threonine protein kinase that 
has been recently linked to tumor development and progression. 
In the last ten years, several studies have demonstrated that Cdk5 is active not 
only in neurons, as previously thought, but also in several non-neuronal 
tissues55 and it is involved in many different physiological, such as gene 
transcription, apoptosis and migration, and pathological conditions, such as 
Alzheimer’s disease. Several groups have recently demonstrated a link 
between CDK5 and a variety of human cancers. In particular, the importance 
of CDK5 activity for cancer cell migration and invasion and, consequently, for 
tumor progression, has been well documented for different solid tumors, such 
as breas197, prostate110, lung198 and pancreatic104 cancers. Instead, only few 
studies elucidate CDK5 role in hematological malignancies, such as 
leukemia199 and multiple myeloma200, but no prior studies have shown the 
role of Cdk5 in lymphoma to date.   
In this study, we investigated if CDK5 could play an important role in 
DLBCL. In preliminary data, we observed that CDK5 protein expression is 
increased in several hematological malignancies cell lines, such as Hodgkin 
lymphoma, Burkitt lymphoma and B-Cell Chronic Lymphocytic Leukemia, 
compared to B lymphocytes from healty donors. Then, we focused on DLBCL 
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and we showed for the first time that CDK5 expression was increased in all of 
the human DLBCL cell lines we collected compared to control B lymphocytes, 
at both protein and mRNA levels, suggesting that an increased transcription 
of the gene is implicated.  
Courapied and colleagues have shown that upon DNA damage, CDK5 
phosphorylates STAT3 at Serine 727 and activates the transcription of genes 
involved in DNA repair, such as Eme1201, and Lin and colleagues have found 
that CDK5 regulates cell proliferation of medullary thyroid tumor cells 
through STAT3 activation202. Thus, to investigate a potential link between the 
expression of CDK5 and the phosphorilation level of STAT3 in DLBCL, we 
silenced CDK5 by using shRNA and we found a reduction in STAT3 
phosphorilation level at S727.  In agreement with these data, we observed a 
higher level of phosphorilation in DLBCL cell lines in which CDK5 is 
overexpressed compared to B lymphocytes from healthy donors.  
To study the function of CDK5 in DLBCL, we silenced the protein and we 
observed a significant decrease in tumor cell proliferation rate and a 
promotion of apoptotic events. This effects were rescued when CDK5 protein 
was restored by the expression of a recombinant CDK5 coding DNA 
sequence. We obtained similar results when we down-regulated the activator 
of Cdk5, p35. The overexpression of p35, instead, increased tumor cell 
proliferation and reduced apoptosis, as expected. These results demonstrated 
that CDK5 and p35 have a fundamental role in proliferation and apoptosis 
regulation of DLBCL cells.  
Interesting, we found that p35 protein was higher in the cancer cells 
compared to healthy B lymphocytes, but this difference was not confirmed at 
the mRNA level. We hypothesized that the discrepancy between the p35 high 
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protein expression and the low mRNA level was due to the presence of an 
additional post-transcriptional regulatory process, able to inhibit the 
translation of p35 in normal cells, but absent on tumor cells. Indeed, we found 
that miR-26a directly regulates p35 expression in DLBCL cell lines, by binding 
its 3’ UTR, and that the level of miR-26a in tumor cells is inversely correlated 
with p35 level. In fact, we showed that up-regulation of miR-26a significantly 
reduced p35 level in DLBCL cells and overexpression of miR-26a decreased 
the luciferase reporter activity of the p35 wild-type 3’-UTR, but not of the 
mutant. MiR-26a has a controversial role in cancer. In fact, its expression 
deregulation has been correlated with tumorigenesis and cancer progression, 
acting as a oncogene in some types of cancer, but also with tumor suppressor 
in other types of tumors. Here, for the first time, we studied the role of miR-
26a deregulation in DLBCL tumor growth using in vitro and in vivo assays. 
We showed that miR-26a level was significantly lower in DLBCL cell lines 
compared to B lymphocytes from healthy donors, and that miR-26a 
overexpression suppressed proliferation and promoted apoptosis in tumor 
cell lines. Moreover, miR-26a inhibits DLBCL tumor growth and promotes 
tumor necrosis in NOD/SCID mice. These results indicate that miR-26a acts 
as a tumor suppressor in DLBCL.  
The effects of miR-26a modulation on cell proliferation, apoptosis, tumor 
growth in DLBCL were accompanied by changes in p35 levels and CDK5 
activities. Concomitant expression of a recombinant 3’UTR truncated p35 
completely abrogated the effects induced by miR-26a. These data revealed 
that miR-26a directly regulates p35, which is one of the most important 
downstream mediators of miR-26a function in DLBCL.  
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All together, these findings support the notion that the CDK5/P35 complex 
mediates the tumor-suppressive function of miR-26a, and that p35 
deregulation through miR-26a plays an important role in tumor growth and 
may be considered as a novel prognostic marker and a potential therapeutic 
target for DLBCL. 
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